Hepatic Impairment Study
Research payments
$3,452,522
Through program year 2025, $3,452,522 in research payments was reported against Hepatic Impairment Study, across 40 payments.
- Paid by (largest first)
- Boehringer Ingelheim Pharmaceuticals, Inc.; Boehringer Ingelheim International GmbH; H. Lundbeck A S
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
4 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $28,100 | 2 |
| 2024 | Research | $691,186 | 11 |
| 2023 | Research | $2,419,924 | 15 |
| 2022 | Research | $313,312 | 12 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
4 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.